Jan 10, 2022 8:30am EST Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer
Jan 03, 2022 8:30am EST Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022
Dec 13, 2021 8:30am EST Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Dec 08, 2021 8:00am EST Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
Nov 18, 2021 8:30am EST Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd
Nov 18, 2021 8:00am EST Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500
Nov 08, 2021 8:30am EST Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021
Oct 13, 2021 8:30am EDT Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Sep 20, 2021 8:30am EDT Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
